Endonovo Therapeutics, Inc.
Other OTCTotal Valuation
Endonovo Therapeutics, Inc. carries a market capitalization of 31,875.00, placing it among publicly traded companies globally. Its enterprise value stands at 7.07M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 31,875.00 |
| Enterprise Value | 7.07M |
Share Statistics
Endonovo Therapeutics, Inc. currently has 1.21B shares outstanding.
| Shares Outstanding | 1.21B |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | 0.00 |
| P/TBV Ratio | -0.01 |
| P/FCF Ratio | 2.29 |
| P/OCF Ratio | 2.29 |
Enterprise Valuation
| EV / Sales | N/A |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | 5.38 |
Financial Position
Endonovo Therapeutics, Inc. maintains a current ratio of 0.00, meaning it holds 0.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -24.78, indicating conservative leverage, while an interest coverage ratio of -0.75 demonstrates limited ability to service its debt obligations.
| Current Ratio | 0.00 |
| Quick Ratio | 0.00 |
| Debt / Equity | -24.78 |
| Debt / EBITDA | -7.41 |
| Interest Coverage | -0.75 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -1,482.57 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Endonovo Therapeutics, Inc.'s stock has declined approximately -66.66667% over the past 52 weeks. The 50-day moving average sits at 0.00, while the 200-day moving average is 0.00.
| Beta (5Y) | N/A |
| 52-Week Price Change | -66.66667% |
| 50-Day Moving Average | 0.00 |
| 200-Day Moving Average | 0.00 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -930,709.00, while operating income came in at -1.23M.
| Revenue | N/A |
| Gross Profit | -1.00 |
| Operating Income | -1.23M |
| Pretax Income | -2.46M |
| Net Income | -2.46M |
| EBITDA | -930,709.00 |
| EBIT | -1.23M |
| Earnings Per Share (EPS) | 0.00 |
Balance Sheet
Endonovo Therapeutics, Inc. holds 230.00 in cash and equivalents against 6.90M in total debt, resulting in a net debt position of 6.90M. Total book value stands at -72.00M, with working capital of -27.74M providing operational flexibility.
| Cash & Cash Equivalents | 230.00 |
| Total Debt | 6.90M |
| Net Debt | 6.90M |
| Equity (Book Value) | -72.00M |
| Book Value Per Share | -0.07 |
| Working Capital | -27.74M |
Cash Flow
Endonovo Therapeutics, Inc. produced 76,629.00 in operating cash flow over the past twelve months.
| Operating Cash Flow | 76,629.00 |
| Capital Expenditures | N/A |
| Free Cash Flow | 76,629.00 |
| FCF Per Share | 0.00 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | 45.79 |
| FCF Yield | 43.62 |
Stock Splits
Endonovo Therapeutics, Inc.'s most recent stock split took place on December 20, 2019 with a 1000:1 split ratio.
| Last Split Date | 12/20/2019 |
| Split Ratio | 1000:1 |
Scores
Endonovo Therapeutics, Inc. posts an Altman Z-Score of -7,706.95, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -7,706.95 |